OpEd: Drug Importation Crisis: Terror Politics to the Rescue!

The FDA just played the terrorist trump card in its battle against the legalization of the reimportation of drugs.

Pharma Marketing News Vol. 3, #8 (September 2004)

Dear Reader, Welcome to the September 2004 archive of Pharma Marketing News. Vol. 3, No. 8: September 2004 - CONTENTS ...

Pharma Marketing News Vol. 3, #8 (September 2004)

Welcome to the latest issue of Pharma Marketing News. This is the Executive Summary version. You can download the full-text version of the complete newsletter at: https://www.pharma-mkting.com/news/pmnews3_8hsubx.pdf...

The Targeted Model: The Future of Pharmaceutical Marketing?

Remember the good days of pharmaceutical marketing? When pharmaceutical reps and doctors had personal relationships? When the sales rep was the dominant influencer of physician prescribing behavior? When reps were knowledgeable and provided the physician with useful information that couldn't be gotten anywhere else?

OpEd: The Price of Drugs

The typical pharma industry responses to criticism about rising drug prices may make economic sense, but they do not resonant with consumers' perceptions and emotions. In fact, sometimes it seems more like a slap in the face than a consoling pat on the back.

Pharma Marketing News Vol. 3, #7 (July/August 2004) Archive

Dear Reader, Welcome to the archive of the July/August, 2004 issue Pharma Marketing News. Vol. 3, No. 7: July/August 2004 - CONTENTS...

Pharma Marketing News Vol. 3, #7 (July/August 2004) Executive Summary

Dear Reader: Welcome to the executive summary of the July/August, 2004 issue of Pharma Marketing News. This edition offers you reprints from the current issue...

Pharma Marketing News Vol. 3, #8 (September 2004) Executive Summary

Dear Reader: Welcome to the executive summary of the July/August, 2004 issue of Pharma Marketing News. This edition offers you reprints from the current issue...

California’s Physician Prescribing Act: A History of Twists and Turns

This article traces the changes in California's Physician Prescribing Act (AB 262) as it wended its way through various committees. It describes the provisions that may limit the use of physician prescribing data by pharmaceutical marketers, identifies organizations that have taken a position in favor and against the bill, and discusses the arguments on both sides of the issue.

A Crisis in Professional Detailing

Two physicians -- one a specialist (cardiologist) and one a primary care physician -- offered their insights on how pharmaceutical companies can improve their relationships with physicians.
- Advertisement -